Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.53 | -0.07 | 0.37 |
| FCF Yield | -0.67% | -2.66% | -2.01% | -1.71% |
| EV / EBITDA | -98.07 | 218.38 | -26.06 | -47.00 |
| Quality | ||||
| ROIC | -9.31% | 1.93% | -35.31% | -11.95% |
| Gross Margin | 0.00% | 99.90% | -407.88% | 78.84% |
| Cash Conversion Ratio | 0.75 | -6.24 | 0.55 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -13.08% | -13.15% | -42.18% | -45.92% |
| Free Cash Flow Growth | 63.06% | -17.61% | -28.75% | 49.84% |
| Safety | ||||
| Net Debt / EBITDA | 2.48 | -12.65 | 1.49 | 2.88 |
| Interest Coverage | 376.48 | 68.32 | -1,237.79 | -464.43 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 153.97 | -10,798.75 | 60.31 | -488.20 |